支气管舒张反应性的患病率、诊断效用及相关特征
NOVELTY前瞻性队列研究纳入18个国家初级和二级医疗中12岁及以上、医生诊断哮喘、哮喘+慢阻肺或慢阻肺的患者,分别用2005和2021年ERS/ATS标准计算支气管舒张反应性(BDR)阳性比例,并分析其相关特征,发现BDR患病率18%~30%,与更低肺功能和更高症状负担相关。
要点
- BDR患病率:哮喘19.7%、哮喘+慢阻肺29.6%、慢阻肺24.7%(2005标准)。
- 2021标准下BDR患病率分别为18.1%、23.3%、18.0%,低于2005标准。
- 哮喘患者中BDR(2021)与更高FeNO、更低肺功能、更高症状负担相关。
核心结论
- 慢性气道疾病治疗中BDR患病率为18%~30%,2021标准较2005标准略低。
- BDR与更低肺功能和更高症状负担相关,提示其可作为可治疗特征。
- BDR作为哮喘诊断工具或临床试验纳入标准的有效性受到质疑。
研究设计与样本
- NOVELTY前瞻性队列研究,覆盖18个国家初级和二级医疗。
- 纳入12岁及以上、医生诊断为哮喘、哮喘+慢阻肺或慢阻肺的患者。
- 哮喘3519例,哮喘+慢阻肺833例,慢阻肺2436例。
主要发现
- 2005标准下BDR患病率:哮喘19.7%,哮喘+慢阻肺29.6%,慢阻肺24.7%。
- 2021标准下BDR患病率:哮喘18.1%,哮喘+慢阻肺23.3%,慢阻肺18.0%。
- 哮喘患者中BDR(2021)与更高FeNO、更低肺功能、更高症状负担、更频繁住院及更多使用三联疗法、口服糖皮质激素或生物制剂相关。
- 慢阻肺患者中BDR(2021)与更低肺功能和更高症状负担相关。
关键数值与推荐
- 2005年ERS/ATS标准:ΔFEV1或ΔFVC≥12%且≥200 ml。
- 2021年ERS/ATS标准:ΔFEV1或ΔFVC>10%预计值。
临床怎么用
- 在已治疗的慢性气道疾病患者中,BDR阳性率较高,需结合临床背景解读。
- BDR与更低肺功能和更高症状负担相关,可考虑作为可治疗特征进行管理。
- BDR不宜单独作为哮喘诊断工具或临床试验纳入标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The prevalence and diagnostic utility of bronchodilator responsiveness (BDR) in a real-life setting is unclear. Objective: To explore this uncertainty in patients aged ⩾12 years with physician-assigned diagnoses of asthma, asthma and chronic obstructive pulmonary disease (COPD), or COPD in NOVELTY, a prospective cohort study in primary and secondary care in 18 countries. Methods: The proportion of patients with a positive BDR test in each diagnostic category was calculated using 2005 (ΔFEV1 or ΔFVC ⩾12% and ⩾200 ml) and 2021 (ΔFEV1 or ΔFVC >10% predicted) European Respiratory Society/American Thoracic Society criteria. Measurements and Main Results: We studied 3,519 patients with a physician-assigned diagnosis of asthma, 833 with a diagnosis of asthma + COPD, and 2,436 with a diagnosis of COPD. The prevalence of BDR was 19.7% (asthma), 29.6% (asthma + COPD), and 24.7% (COPD) using 2005 criteria and 18.1%, 23.3%, and 18.0%, respectively, using 2021 criteria. Using 2021 criteria in patients diagnosed with asthma, BDR was associated with higher fractional exhaled nitric oxide; lower lung function; higher symptom burden; more frequent hospital admissions; and greater use of triple therapy, oral corticosteroids, or biologics. In patients diagnosed with COPD, BDR (2021) was associated with lower lung function and higher symptom burden. Conclusions: BDR prevalence in patients with chronic airway diseases receiving treatment ranges from 18% to 30%, being modestly lower with the 2021 than with the 2005 European Respiratory Society/American Thoracic Society criteria, and it is associated with lower lung function and greater symptom burden. These observations question the validity of BDR as a key diagnostic tool for asthma managed in clinical practice or as a standard inclusion criterion for clinical trials of asthma and instead suggest that BDR be considered a treatable trait for chronic airway disease.
引用
- Beasley R, Hughes R, Agusti A, et al. Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness. Am J Respir Crit Care Med. 2024. PMID: 38029294. doi:10.1164/rccm.202308-1436OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。